Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn’s | Global News Avenue

Teva Pharmaceuticals’ U.S.-traded shares (Teva) and Sanofi (cut) The drug gained popularity on Tuesday after two drugmakers reported positive results from studies of its treatment of ulcerative colitis (UC) and Crohn’s disease.

Phase 2b, Teva said in a news release Tuesday. trial Studies of the human monoclonal antibody duvakitug found the substance met the primary endpoint. The report pointed out that the clinical remission rates of UC patients given low-dose and high-dose drugs were 36.2% and 47.8% respectively, which were higher than those of patients receiving placebo.

For Crohn’s disease patients, the results were 26.1% and 47.8%, respectively, which were also higher than those taking placebo.

Teva says first study into Crohn’s disease

Teva said it was “the first and only randomized, placebo-controlled study to evaluate the impact of an anti-TL1A monoclonal antibody in (Crohn’s disease).” It added that the companies expected to present the results at a scientific forum next year. Gives detailed results.

Dr. Houman Ashrafian, Director research and development Sanofi said the results suggest “duvakitug may represent the next frontier in the treatment of ulcerative colitis and Crohn’s disease.”

Teva and Sanofi said they plan to initiate Phase 3 trials of duvakitug, pending regulatory discussions.

On Tuesday, Teva’s U.S.-listed shares hit their highest level in six years, rising more than 26% to $20.88 recently. The stock has nearly doubled in price this year. Sanofi’s U.S.-listed shares rose more than 7% to $49.10.